Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer

Published:2018-05 Issue:5 Volume:33 Page:843-852.e4
ISSN:1535-6108
Container-title:Cancer Cell
language:en
Short-container-title:Cancer Cell

Author:

Hellmann Matthew D.^ORCID,Nathanson Tavi,Rizvi Hira,Creelan Benjamin C.,Sanchez-Vega Francisco,Ahuja Arun,Ni Ai,Novik Jacki B.,Mangarin Levi M.B.,Abu-Akeel Mohsen,Liu Cailian,Sauter Jennifer L.,Rekhtman Natasha,Chang Eliza,Callahan Margaret K.,Chaft Jamie E.,Voss Martin H.,Tenet Megan,Li Xue-Mei,Covello Kelly,Renninger Andrea,Vitazka Patrik,Geese William J.,Borghaei Hossein,Rudin Charles M.,Antonia Scott J.,Swanton Charles,Hammerbacher Jeff,Merghoub Taha,McGranahan Nicholas,Snyder Alexandra,Wolchok Jedd D.

Funder

The Conquer Cancer Foundation of ASCO

Bristol-Myers Squibb International Immuno-Oncology Network

Geoffrey Beene Cancer Research Center

Ludwig Trust

Memorial Sloan Kettering Cancer Center

Parker Institute for Cancer Immunotherapy

Druckenmiller Center for Lung Cancer Research

Swim Across America

Stand Up to Cancer-American Cancer Society Lung Cancer Dream Team Translational Research

Bristol-Myers Squibb

AstraZeneca

Roche

Genentech

MedImmune

Millennium Pharmaceuticals

Eli Lilly

Merck

Celgene

Biomarin

Neon Therapeutics

Publisher

Elsevier BV

Subject

Cancer Research,Cell Biology,Oncology

Reference61 articles.

1. Evolution of neoantigen landscape during immune checkpoint blockade in non-small cell lung cancer;Anagnostou;Cancer Discov.,2017

2. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer;Borghaei;N. Engl. J. Med.,2015

3. CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity;Burr;Nature,2017

4. Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas

5. First-line nivolumab in stage IV or recurrent non-small-cell lung cancer;Carbone;N. Engl. J. Med.,2017

Cited by 828 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MDM2 inhibitors in cancer immunotherapy: Current status and perspective;Genes & Diseases;2024-11

2. Antithetical impacts of deleterious LRP1B mutations in non-squamous and squamous NSCLCs on predicting benefits from immune checkpoint inhibitor alone or with chemotherapy over chemotherapy alone: retrospective analyses of the POPLAR/OAK and CHOICE-01 trials;Science China Life Sciences;2024-09-12

3. Comparative analysis of PD-L1 expression and molecular alterations in primary versus metastatic lung adenocarcinoma: a real-world study in China;Frontiers in Oncology;2024-09-11

4. Characterizing the Tumor Microenvironment and Its Prognostic Impact in Breast Cancer;Cells;2024-09-10

5. MYC plus class IIa HDAC inhibition potentiates mitochondrial dysfunction in non-small cell lung cancer;2024-09-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3